Lifetime costs (€) | Lifetime QALYs | ICER (€/QALY gained) | |||||
---|---|---|---|---|---|---|---|
Apixaban | Warfarin | Diff. | Apixaban | Warfarin | Diff. | ||
Base case | 16,197 | 15,936 | 261 | 7.19 | 7.05 | 0.14 | 1824 |
Without discounting | 20,647 | 20,442 | 205 | 8.99 | 8.80 | 0.19 | 1060 |
Sensitivity analyses | |||||||
CHADS 0–1 | 15,491 | 14,931 | 560 | 7.25 | 7.12 | 0.13 | 4347 |
CHADS 2 | 16,151 | 15,708 | 443 | 7.20 | 7.07 | 0.13 | 3387 |
CHADS 3–6 | 17,012 | 17,266 | −254 | 7.13 | 6.96 | 0.17 | Dominant |
TTR < 52.38 % | 16,047 | 17,150 | −1104 | 7.19 | 6.97 | 0.22 | Dominant |
52.38 % ≤ TTR < 66.02 % | 17,397 | 16,170 | 1226 | 7.14 | 7.04 | 0.10 | 12,312 |
66.02 % ≤ TTR < 76.51 % | 16,164 | 15,131 | 1033 | 7.20 | 7.10 | 0.10 | 10,386 |
TTR ≥ 76.51 % | 15,150 | 15,249 | −98.23 | 7.25 | 7.10 | 0.15 | Dominant |
No treatment discontinuations after trial period | 19,473 | 19,042 | 431 | 7.24 | 7.04 | 0.21 | 2102 |
Warfarin monitoring cost −50 % | 16,197 | 14,650 | 1546 | 7.19 | 7.05 | 0.15 | 10,817 |
Warfarin monitoring cost +50 % | 16,197 | 17,222 | −1025 | 7.19 | 7.05 | 0.14 | Dominant |